Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections

Oritavancin, a semisynthetic derivative of the glycopeptide antibiotic chloroeremomycin, received the US Food and Drug Administration approval for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria in adults in August 2014. This novel sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitra, Subhashis, Saeed, Usman, Havlichek, Daniel H, Stein, Gary E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500617/
https://www.ncbi.nlm.nih.gov/pubmed/26185459
http://dx.doi.org/10.2147/IDR.S69412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500617/
https://www.ncbi.nlm.nih.gov/pubmed/26185459
http://dx.doi.org/10.2147/IDR.S69412

Ejemplares similares